Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Receivables - Other for 3 consecutive years, with $177000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Other fell 10.15% to $177000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $177000.0 through Dec 2025, down 10.15% year-over-year, with the annual reading at $177000.0 for FY2025, 10.15% down from the prior year.
  • Receivables - Other for Q4 2025 was $177000.0 at Inhibrx Biosciences, down from $727000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $952000.0 in Q2 2024, with the low at $177000.0 in Q4 2025.
  • Average Receivables - Other over 3 years is $565000.0, with a median of $667000.0 recorded in 2023.
  • The sharpest move saw Receivables - Other tumbled 67.55% in 2024, then decreased 10.15% in 2025.
  • Over 3 years, Receivables - Other stood at $607000.0 in 2023, then crashed by 67.55% to $197000.0 in 2024, then dropped by 10.15% to $177000.0 in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $177000.0, $727000.0, and $730000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.